Kyverna (KYTX) announces positive Phase 2 interim KYV-101 data

Kyverna Therapeutics (KYTX) announced positive interim data from the Phase 2 portion of its KYSA-6 Phase 2/3 trial of KYV-101 in generalized myasthenia gravis.

Rhea-AI Filing Summary

Kyverna Therapeutics (KYTX) announced positive interim data from the Phase 2 portion of its KYSA-6 Phase 2/3 trial of KYV-101 in generalized myasthenia gravis. The company will host a conference call at 8:00 a.m. Eastern Time on October 29, 2025 to review the results.

Slides for the call are furnished as Exhibit 99.1. The information was furnished under Item 7.01 and is not deemed “filed” under the Exchange Act.

8-K Event Classification

Item 7.01 — Regulation FD Disclosure

1 item

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Kyverna Therapeutics (KYTX) announce?

Kyverna announced positive interim data from the Phase 2 portion of its KYSA-6 Phase 2/3 trial of KYV-101 in generalized myasthenia gravis.

When is KYTX discussing the KYV-101 results?

Kyverna will host a conference call at 8:00 a.m. Eastern Time on October 29, 2025 to review the interim results.

Where can I find the presentation materials for the KYTX call?

Slides are furnished as Exhibit 99.1 titled “Interim Data for KYSA-6 Phase 2 Clinical Trial of KYV-101 in Generalized Myasthenia Gravis.”

Is the KYTX information considered filed with the SEC?

No. The information in Item 7.01 (including Exhibit 99.1) is furnished and not deemed “filed” under the Exchange Act.

What program is KYV-101 being studied in?

KYV-101 is being studied in the KYSA-6 Phase 2/3 trial for generalized myasthenia gravis.

What is the form of this disclosure by KYTX?

This is an 8-K current report providing a business update under Item 7.01 (Regulation FD Disclosure).

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/29/2025 - 08:00 AM EDT Learn about SEC filing dates

false 0001994702 0001994702 2025-10-29 2025-10-29

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 29, 2025

Kyverna Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware		001-41947		83-1365441
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

5980 Horton St., Suite 550
Emeryville, California		94608
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: (510) 925-2492

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.00001 per share		KYTX		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On October 29, 2025, Kyverna Therapeutics, Inc. (the “Company”) issued a press release announcing positive interim data from the Phase 2 portion from its KYSA-6 Phase 2/3 trial of KYV-101 in generalized myasthenia gravis. The Company will host a conference call at 8:00 a.m. Eastern Time on October 29, 2025 to review the results (the “Conference Call”). A copy of the slides to be used in connection with the Conference Call is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information contained in Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly provided by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

Exhibit Number		Description
99.1		Kyverna Therapeutics, Inc. Presentation - Interim Data for KYSA-6 Phase 2 Clinical Trial of KYV-101 in Generalized Myasthenia Gravis, Conference Call, October 29, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

						KYVERNA THERAPEUTICS, INC.
Date: October 29, 2025				By:		/s/ Marc Grasso
						Marc Grasso Chief Financial Officer